A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Onconova Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 121,011 shares of ONTX stock, worth $71,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,011
Previous 2,600 4554.27%
Holding current value
$71,396
Previous $2,000 3450.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.57 - $1.0 $47,989 - $84,192
84,192 Added 228.66%
121,011 $71,000
Q1 2024

May 15, 2024

BUY
$0.67 - $1.01 $24,668 - $37,187
36,819 New
36,819 $37,000
Q4 2022

Feb 14, 2023

SELL
$0.63 - $0.97 $15,163 - $23,346
-24,069 Reduced 56.29%
18,689 $12,000
Q3 2022

Nov 14, 2022

SELL
$0.95 - $1.45 $15,916 - $24,293
-16,754 Reduced 28.15%
42,758 $38,000

Others Institutions Holding ONTX

About Onconova Therapeutics, Inc.


  • Ticker ONTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,895,600
  • Market Cap $12.3M
  • Description
  • Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...
More about ONTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.